Probiotix Health PLC - Notice of Annual General Meeting - Clarification
Announcement provided by
ProBiotix Health Plc · PBX05/06/2025 17:30
5 June 2025
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
Notice of Annual General Meeting - Clarification
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces, for the avoidance of doubt, that Resolution 3 in the Company's Notice of Annual General Meeting is for the re-election of Steen Andersen, the Company's Chief Executive Officer, as a Director of the Company. The reference to Steen "Anderson" is a typographical error. Existing Forms of proxy for use at the Annual General Meeting remain valid.
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
|
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
Peterhouse Capital Limited Aquis Corporate Adviser and Broker |
|
|
Mark Anwyl Duncan Vasey
|
Tel: 020 7469 0930 |
|
|
|
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach: discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
